July 2007 PBAC OUTCOMES – Subsequent decision to defer

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC OUTCOME AND COMMENT
DOCETAXEL, vial, 20 mg, 80 mg, Taxotere® sanofi-aventis Australia Pty Ltd Major submission	Prostate cancer	Authority required *for treatment of androgen independent (hormone refractory) prostate cancer*.	The PBAC noted that no new efficacy and safety data had been presented, but that a new Australian Utility study had been conducted to elicit utility weights for a new Q-TWiST analysis. Although there were some residual concerns with the Q-TWiST analysis, the PBAC concluded that it was unlikely that further adjustments would alter substantially the resultant incremental cost-effectiveness ratio (ICER). Nevertheless, the PBAC considered that the ICER was unacceptably high. The Committee indicated that, if the sponsor were to offer a price reduction, it would be prepared to consider the matter again out-of-session. The PBAC indicated that any restriction on the listing of docetaxel should stipulate use as first-line chemotherapy, a minimum Karnofsky score of 60%, that dosing must be on a 3-weekly basis (there was no survival difference when weekly dosing was used) and a maximum of 10 cycles. *(See also positive recommendations from July 2007)*
		Sponsor's comments	The sponsor is considering the PBAC proposal